Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
OncoGenex Technologies
ClinicalTrials.gov Identifier:
NCT00487786
First received: June 15, 2007
Last updated: January 14, 2016
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)